ClinicalTrials.gg
Active, not recruitingNCT04573478ALIGNUpdated Jun 4, 2026

Atrasentan in Patients With IgA Nephropathy

A Phase 3 interventional study of Atrasentan and Placebo in IgA Nephropathy and Immunoglobulin A Nephropathy, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 135 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
404
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Glomerulonephritis, IGA by Novartis — 9 open to participants now, 12 under way, 7 of them phase 3. Glomerulonephritis, IGA · Novartis.

Enrollment
3rd of 14
404 · median 108
Started
2020
the only one that year
Phase 3
8 of 18
5 open now
Primary completion
2028-04
later than 4 of 11 live
Registered
4th of 18
by date

Among the 18 studies in Glomerulonephritis, IGA by Novartis, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 3, reaches primary completion later than 4 of the 11 other live ones, and was the 4th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

9 of the 18 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Glomerulonephritis, IGA by Novartis, or all of them as a file.
02

Study summary

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

Read the detailed description

Approximately 320 patients with biopsy-proven IgAN will be randomized to receive 0.75 mg atrasentan or placebo daily for 132 weeks. Subjects receive a maximally tolerated and stable dose of a RAS (renin-angiotensin system) inhibitor [such as angiotensin converting enzyme inhibitor (ACEi) or angiotensin-receptor antagonist (ARB)] as part of standard of care. An exception will be made for subjects who are unable to tolerate RAS inhibitor therapy.

Additional subjects receiving a stable dose of SGLT2i will be enrolled to the study. Enrollment in this SGLT2i stable stratum will be in accordance with local regulations in regions that prescribe SGLT2i and will be independent of the 320 subjects enrolled for the primary and secondary analyses.

The primary objective of the study is to evaluate the effect of atrasentan versus placebo on proteinuria as measured by UPCR. Secondary and tertiary objectives include evaluating the change in kidney function over time as measured by eGFR, safety and tolerability.

Subjects will have assessments of safety and efficacy over 2 ½ years. To facilitate study participation over this time period, where allowed by local regulations, options for remote study visits using telemedicine and home health may be offered.

Subjects who complete treatment through Week 132 and complete the double-blinded portion of the study may be eligible to enroll in the open label (OL) extension of the study to receive atrasentan 0.75 mg daily for up to 48 weeks.

Subjects who complete the 48 weeks of atrasentan treatment in OL extension or who are treated with atrasentan long enough to sufficiently determine its efficacy as per clinical judgement of the Principal Investigator may be optionally re-evaluated for eligibility to participate in the substudy if available at their clinical site. Eligible subjects following re-evaluation may enter the co-administration treatment phase, receiving atrasentan 0.75 mg orally once daily plus zigakibart for 48 weeks.

03

Conditions studied

  • IgA Nephropathy
  • Immunoglobulin A Nephropathy

Keywords

  • Kidney Diseases
  • Kidney Disease, Chronic
  • Urologic Diseases
  • Glomerulonephritis
  • Glomerular Disease
  • Glomerulonephritis, IGA
  • Glomerulopathy
  • Immunoglobulin Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Double-Blind period:

  • -proven IgA nephropathy.
  • Receiving a maximally tolerated dose of RAS inhibitor therapy (ACEi or ARB) that has been stable for at least 12 weeks. Exceptions from this requirement will be made for subjects who are unable to tolerate RAS inhibitor therapy.
  • Total urine protein ≥1 g/day as measured via 24-hour urine collection by central laboratory at Screening.
  • of at least 30 mL/min/1.73 m\^2 at Screening based on the CKD-EPI equation.
  • Willing and able to provide and comply with all study requirements.
  • SGLT2i Stable Stratum Only - Receiving a stable dose of an SGLT2i (per Investigator choice) in addition to a maximally tolerated and optimized dose of a RAS inhibitor that has been stable for at least 12 weeks prior to Screening.
  • All fertile men and who engage in heterosexual intercourse must be willing to abide with highly effective forms of , as specified in the protocol, throughout the study and for 1 month afterward. In WOCBP, use of contraceptive agents must have been started at least 1 month prior to Baseline.

Open-Label Period:

  • Willing and able to provide informed consent and comply with all OL extension study visits and study procedures.
  • Completed treatment through Week 132 and completed the Week 136 visit.
  • All fertile men and WOCBP who engage in heterosexual intercourse must be willing to abide with highly effective forms of contraception, as specified in the protocol, throughout the study and for 1 month afterward. In WOCBP, use of contraceptive agents must have been continued after completing the double-blind portion of the study.

Substudy:

Subjects must meet ALL inclusion criteria to be enrolled.

  • Subjects who provided written informed consent prior to initiation of any substudy-specific activities/procedures and are willing to comply with all substudy visits and substudy procedures.
  • Completion of OL extension treatment through Week 48 visit or treated with atrasentan long enough to sufficiently determine its efficacy as per clinical judgement of the Principal Investigator.
  • Stable on a maximally tolerated dose of ACEi and/or ARB for at least 12 weeks prior to substudy screening visit.
  • All fertile men and WOCBP who engage in heterosexual intercourse must be willing to abide with highly effective forms of contraception, as specified in the protocol

Exclusion criteria

Exclusion Criteria:

Double-blind period:

  • Concurrent diagnosis of another cause of chronic kidney disease including diabetic kidney disease or another primary glomerulopathy.
  • Clinical diagnosis of nephrotic syndrome.
  • BNP value of > 200 pg/mL at Screening.
  • count \<80,000 per μL at Screening.
  • History of organ transplantation (subjects with history of corneal transplant are not excluded).
  • Use of systemic medications.
  • below 9 g/dL at Screening or prior history of blood transfusion for anemia within 3 months of Screening.

Open-label period:

  • \< 25 mL/min/1.73m\^2 or evidence of rapidly decreasing eGFR, including unrecovered acute kidney injury or expected to require renal replacement therapy within 3 months
  • BNP value of > 200 pg/mL at OL Screening.
  • Platelet count \< 80,000 per μL at OL Screening.
  • Hemoglobin below 9 g/dL at OL screening or prior history of blood transfusion for anemia within 3 months of OL Screening.

Substudy:

Subjects must meet NONE of the following exclusion criteria to be enrolled.

  • Participants who are not receiving atrasentan at the time of substudy screening visit in the ALIGN OL extension study phase or had atrasentan interruption for longer than 2 weeks within last 24 weeks of substudy screening visit.
  • ALIGN OL extension participants with insufficient compliance defined as less than 70%
  • Plan to receive any agent (other than atrasentan or zigakibart) or approved treatment for IgAN (other than a RAS inhibitor or SGLT2i). Other ETA receptor antagonists will not be allowed during substudy extension.
  • eGFR \< 25 mL/min/1.73m2 or evidence of rapidly decreasing eGFR, including unrecovered acute kidney injury or expected to require renal replacement therapy within 3 months
  • Ongoing treatment-related SAE or ongoing related severe AESI.
  • Clinical suspicion of rapidly progressive glomerulonephritis (RPGN).
  • Received a within 12 weeks prior to first substudy treatment administration in the substudy or plan to have a live vaccination within 6 months after the last dose of substudy treatment.
  • BNP value of > 200 pg/mL at substudy Screening.
  • Blood pressure >150 mmHg systolic or >95 mmHg diastolic at screening
  • Known history of heart failure or conditions relating to fluid overload.
  • Known history of liver disease or transaminase or values more than twice the at substudy screening.
  • Type 1 diabetes; for type 2 diabetes, exclusion if >8%, evidence of diabetic changes on kidney performed for any reason, or history of diabetic microvascular/macrovascular disease
  • Hemoglobin below 9 g/dL at substudy screening or prior history of blood transfusion for anemia within 3 months of substudy Screening.
  • Newly diagnosed or history of .
  • Pregnancy, breast feeding, or intent to become pregnant during the substudy period and until 24 weeks after last dose for females.
  • Intent to father a child or donate sperm during the substudy period and until 24 weeks after last dose for males.
  • History of an alcohol or illicit drug-related disorder within the past 3 years.
  • History or evidence of any other clinically significant medical disorder, condition, disease, or laboratory finding that, in the discretion of the Investigator, constitutes an uncertain or unfavorable benefit-risk for continued long-term therapy with zigakibart.
  • Use of systemic therapy (including budesonide) or other immunosuppressive therapy.
  • Current severe infection at the time of first substudy treatment in the substudy or history of recurrent, severe, infections as determined by the Investigator.
  • Any confirmed or suspected immunosuppressive or immune-deficient state.
  • Newly diagnosed positive serology for hepatitis A virus IgM antibodies (anti-HAV IgM), surface antigen (HBsAg), detectable hepatitis B virus (HBV) DNA, virus (HCV) antibodies (participants who completed treatment and are persistently antibody positive but have documentation of negative HCV polymerase chain reaction [PCR] will be allowed), or antibodies to -1 and/or HIV-2.
  • Prior exposure to any therapy directed against APRIL.
  • History of a previous severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis.
  • Screening weight \<45 kg or >150 kg
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
404 participants (actual)

Study arms

  • Experimental
    Atrasentan

    Double-blind Period: Once daily oral administration of 0.75 mg atrasentan for 132 weeks. Open-label Extension Period: Once daily oral administration of 0.75 mg atrasentan for 48 weeks after completion of 132 weeks on atrasentan or placebo. Substudy period: Once daily oral administration of 0.75 mg atrasentan + zigakibart for 48 weeks after completion of OL extension period

    Drug: Atrasentan · Drug: Zigakibart

  • Placebo comparator
    Placebo

    Double-blind Period: Once daily oral administration of placebo for 132 weeks

    Drug: Placebo

Interventions

  • Film-coated tablet

    Also known as: CHK-01, Atrasentan Hydrochloride, ABT-627

  • DrugPlacebo

    Film-coated tablet

  • pre-filled syringes with needle safety device

    Also known as: FUB523, BION-1301

06

What researchers measure

Primary outcomes

  1. Double-blind period: Change in proteinuria

    The change in urine protein:creatinine ratio (UPCR) from baseline to Week 36. (non-SGLT2i stratum)

    Time frame: Up to Week 36 or approximately 9 months

  2. Open-label period: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs)

    Type, incidence, severity, seriousness, and relatedness of TEAEs.

    Time frame: From open-label baseline up to end of treatment visit, up to 48 weeks

  3. Open-label period: Number of Subjects With Adverse Events of Special Interest (AESI) Including Events of Fluid Overload

    Incidence, severity, seriousness, and relatedness AESIs.

    Time frame: From open-label baseline up to end of treatment visit, up to 48 weeks

  4. Substudy period: Number of subjects with TEAEs

    Type, incidence, severity, seriousness, and relatedness of TEAEs

    Time frame: From substudy baseline to end of treatment, up to 48 weeks

  5. Substudy period: Number of subjects with AESI

    Incidence, severity, seriousness, and relatedness AESIs.

    Time frame: From substudy baseline to end of treatment, up to 48 weeks

Secondary outcomes

  1. Double-blind period: Change in eGFR

    Change from Baseline to final study visit (Week 136, 4 weeks post end of treatment) using the chronic kidney disease-epidemiology collaboration (CKD-EPI) creatinine equation (non-SGLT2i stratum)

    Time frame: Up to Week 136, 4 weeks post end of treatment

  2. Double-blind period: Percent of subjects meeting the first composite endpoint

    Percent of subjects in the non-SGLT2i stratum meeting the composite endpoint of experiencing at least one of the following during the study: * At least a 30% reduction in eGFR sustained for at least 30 days * eGFR \<15 mL/min/1.73m\^2, sustained for at least 30 days * Chronic dialysis ≥30 days * Kidney transplantation * All-cause mortality

    Time frame: Up to approximately 2.6 years

  3. Double-blind period: Percent of subjects meeting the second composite endpoint

    Percent of subjects in the non-SGLT2i stratum meeting the composite endpoint of experiencing at least one of the following during the study: * At least a 40% reduction in eGFR sustained for at least 30 days * eGFR \<15 mL/min/1.73m\^2, sustained for at least 30 days * Chronic dialysis ≥30 days * Kidney transplantation * All-cause mortality

    Time frame: Up to approximately 2.6 years

  4. Double-blind period: Percent of subjects achieving reduction of proteinuria to < 1 g/day at Week 36

    Percentage of subjects with reduction of proteinuria to \< 1 g/day and a 25% decrease in total urine protein from Baseline (non-SGLT2i stratum).

    Time frame: Baseline to Week 36

  5. Double-blind period: Number of Subjects With TEAEs

    Type, incidence, severity, seriousness, and relatedness of TEAEs.

    Time frame: From first dose of study drug up to 4 weeks post end of treatment in double-blind period, 136 weeks

  6. Double-blind period: Number of Subjects With AESI Including Events of Fluid Overload

    Incidence, severity, seriousness, and relatedness AESIs.

    Time frame: From first dose of study drug up to 4 weeks post end of treatment in double-blind period, 136 weeks

  7. Open-label period: Change in proteinuria

    Change in UPCR based on 24-hour urine collection.

    Time frame: Open-label Baseline to open-label Week 36

  8. Open-label period: Change in eGFR

    Change from open-label Baseline to open-label Week 52 using the CKD-EPI creatinine equation.

    Time frame: Open-label Baseline to open-label Week 52

07

Study locations

135 sites

Showing the first 100 of 135 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Heerspink HJL, Jardine MJ, Kohan DE, Lafayette R, Levin A, Liew A, Zhang H, Noronha IL, Mastroianni-Kirsztajn G, Chow S, Choi DE, Lv J, Trimarchi H, Fu P, Guenther S, Yang S, Liu J, Rahalkar S, Lodha A, Dahlke M, Kollins D, Barratt J; ALIGN study group. Atrasentan in patients with IgA nephropathy (ALIGN): final 2.5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2026 Jun 13;407(10546):2387-2401. doi: 10.1016/S0140-6736(26)00960-8. Epub 2026 Jun 4. PubMed 42242268 ↗
  • Kuo JJ, Wu J, Gunawan MG, McConnell MT, Lester J, Naidu NA, Nieh CH, Surendradoss J, Kano T, Suzuki Y, Olson NE, Cox JH. Effects of Atrasentan on Kidney Gene Transcription, Mesangial Cell Proliferation, and Proteinuria in IgA Nephropathy. Kidney360. 2026 May 1;7(5):1003-1016. doi: 10.34067/KID.0000001000. Epub 2025 Dec 24. PubMed 41442197 ↗
  • Heerspink HJL, Jardine M, Kohan DE, Lafayette RA, Levin A, Liew A, Zhang H, Lodha A, Gray T, Wang Y, Renfurm R, Barratt J; ALIGN Study Investigators. Atrasentan in Patients with IgA Nephropathy. N Engl J Med. 2025 Feb 6;392(6):544-554. doi: 10.1056/NEJMoa2409415. Epub 2024 Oct 25. PubMed 39460694 ↗
  • Schiffrin EL, Pollock DM. Endothelin System in Hypertension and Chronic Kidney Disease. Hypertension. 2024 Apr;81(4):691-701. doi: 10.1161/HYPERTENSIONAHA.123.21716. Epub 2023 Dec 7. PubMed 38059359 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Apr 2028, 88 months after the start.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 88 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2020
First posted
Oct 5, 2020
StartActual
Dec 11, 2020
Primary completionEst.
Apr 14, 2028
CompletionEst.
Apr 14, 2028
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04573478
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Dec 11, 2020
Primary completion
Apr 14, 2028 (estimated)
Completion
Apr 14, 2028 (estimated)
Last update
Jun 4, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atrasentan

Start the discussion